T1	Participants 375 551	one nicotine transdermal system (Nicoderm, Marion Merrell Dow Inc, Kansas City, Mo, and ALZA Corporation, Palo Alto, Calif) in a population who were allowed to continue smoking
T2	Participants 1012 1045	186 subjects completing the study
